Trials / Unknown
UnknownNCT05419739
Prognostic Value of Pediatric GCS-Pupil Score in Pediatric Patients With Traumatic Brain Injury
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 128 (estimated)
- Sponsor
- Uludag University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
There are studies reporting that the survival rate in pediatric patients with abnormal pupillary response is 23% and that pupillary response is effective on mortality and patient outcomes. Studies in the literature examining the effect of pupillary response on mortality and outcome in pediatric patients with traumatic brain injury reported that bilaterally dilated pupils were associated with a higher mortality rate. Considering the literature results, we believe that obtaining the GCS-Pupil score by combining GCS and pupillary reaction in pediatric patients with traumatic brain injury will be effective in predicting patient outcomes.
Detailed description
Obtaining a GCS-Pupil score using the total GCS score: 0 points are given for pupillary reaction if both pupils react to light, 1 point if one pupil does not react to light, and 2 points if both pupils do not react to light. Total GCS-P score is calculated by the formula of Eye Response + Verbal Response + Motor Response - Pupil Reaction and scores between 1-15. In the study, the worst GCS and current pupillary light reaction score in the first 24 hours will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Glasgow coma scale | This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points). |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-07-01
- Completion
- 2023-07-01
- First posted
- 2022-06-15
- Last updated
- 2022-06-22
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT05419739. Inclusion in this directory is not an endorsement.